Citius Oncology (CTOR) Stock: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.95
-0.03 (-3.06%)
âŧ
5d:
-9.52%
30d:
+22.16%
90d:
+34.01%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CTOR is fairly priced but lacks strong directional signals. At 25.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CTOR is fairly priced but lacks strong directional signals. At 25.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.95, which is considered fair relative to its 30-day fair value range of $0.82 to $1.04. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.5) compared to its historical average (4.8). At these levels, the market is pricing in 25.3% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a uptrend. Immediate support is located at $0.91, while resistance sits at $1.15. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CTOR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+321.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTOR is in a uptrend. Immediate support is located at $0.91, while resistance sits at $1.15. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CTOR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+321.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.82 -
$1.04
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
40.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 321.1% below Wall St target ($4.00)
- BEARISH: Market expects 25.3% growth - appears too optimistic based on history
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.82 -
$1.04
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.91
Resistance Level
$1.15
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.50
Wall Street Target
$4.00
(+321.1%)
Valuation Premium vs History
+25.3% premium
PE vs Historical
9.5 vs 4.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+25.3%
(market-implied from PE analysis)
1-Year Target
$1.19
(+25%)
2-Year Target
$1.49
(+57%)
3-Year Target
$1.87
(+97%)
3-Yr Target (if PE normalizes)
(PE: 10â5)
PE COMPRESSION
$0.94
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 04, 2026 2:10 AM ET
Data refreshes hourly during market hours. Next update: 3:10 AM
Data refreshes hourly during market hours. Next update: 3:10 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 47 HOLD |